101 related articles for article (PubMed ID: 7719379)
21. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
22. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
23. Combined interleukin 1 beta/interleukin 2 treatment in mice: synergistic myelostimulatory activity and protection against cyclophosphamide-induced myelosuppression.
Proietti E; Tritarelli E; Gabriele L; Testa U; Greco G; Pelosi E; Gabbianelli M; Belardelli F; Peschle C
Cancer Res; 1993 Feb; 53(3):569-76. PubMed ID: 8425189
[TBL] [Abstract][Full Text] [Related]
24. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.
Clark DA; Gorczynski RM; Blajchman MA
Transfusion; 2008 May; 48(5):814-21. PubMed ID: 18298594
[TBL] [Abstract][Full Text] [Related]
25. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.
Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T
Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of tumor growth in a mouse fibrosarcoma after interleukin 2 application.
Borberg H; Abdallah A; Schwuléra U; Sonneborn H
Immunobiology; 1986 Sep; 172(3-5):383-90. PubMed ID: 3492435
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of pulmonary metastases using monoclonal antibody to T-cell suppressor factor and interleukin 2.
Kim B; Warnaka P; Iverson M; Imbembo AL
Arch Surg; 1987 Dec; 122(12):1455-9. PubMed ID: 3500692
[TBL] [Abstract][Full Text] [Related]
28. Phenotype and cytolytic activity of mouse tumor-bearer splenocytes and tumor-infiltrating lymphocytes from K-1735 melanoma metastases following anti-CD3, interleukin-2, and tumor necrosis factor-alpha combination immunotherapy.
Yang SC; Fry KD; Grimm EA; Roth JA
J Immunother (1991); 1991 Oct; 10(5):326-35. PubMed ID: 1790140
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7.
Dubinett SM; Huang M; Dhanani S; Economou JS; Wang J; Lee P; Sharma S; Dougherty GJ; McBride WH
J Natl Cancer Inst; 1995 Apr; 87(8):593-7. PubMed ID: 7752257
[TBL] [Abstract][Full Text] [Related]
30. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
Chou T; Bertera S; Chang AE; Shu S
J Immunol; 1988 Sep; 141(5):1775-81. PubMed ID: 3261761
[TBL] [Abstract][Full Text] [Related]
31. Local hyperthermia abrogates the anti-immunotherapeutic effect of interleukin-8.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1994 Jun; 56(2):102-6. PubMed ID: 8007673
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor effect of electrotherapy alone or in combination with interleukin-2 in mice with sarcoma and melanoma tumors.
Sersa G; Miklavcic D; Batista U; Novaković S; Bobanović F; Vodovnik L
Anticancer Drugs; 1992 Jun; 3(3):253-60. PubMed ID: 1525406
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
34. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
35. Combination chemo-immunotherapy of murine solid tumor with OK-432, G-CSF, IL-2, and chemotherapeutics.
Iida S; Matsuoka S; Kudo C; Moriya Y; Yoshida T; Saito M
Int J Immunopharmacol; 1995 Dec; 17(12):973-80. PubMed ID: 8964656
[TBL] [Abstract][Full Text] [Related]
36. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
Pendurthi TK; Schlom J; Primus FJ
J Immunother (1991); 1991 Feb; 10(1):2-12. PubMed ID: 2012797
[TBL] [Abstract][Full Text] [Related]
37. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
38. [Induction of manganese superoxide dismutase by an immunopotentiator as a mechanism of inhibiting of malignant progression of murine tumor cells].
Habelhah H
Hokkaido Igaku Zasshi; 1998 Sep; 73(5):519-29. PubMed ID: 9846281
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor alpha mediates the antitumor effect of combined interleukin-2 and whole body hyperthermia.
Fritz KL; Koziol S; Fabian DF; Lefor AT
J Surg Res; 1996 Jan; 60(1):55-60. PubMed ID: 8592432
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T cells and prevents the development of unresponsiveness.
Zier KS; Salvadori S; Cronin KC; Gansbacher B
Cancer Gene Ther; 1994 Mar; 1(1):43-50. PubMed ID: 7621237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
